MIAMI, FL / ACCESSWIRE / May 18, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy
09.08.2022 - DGAP-News: Kadimastem Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment 09.08.2022 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Kadimastem Ltd. (TASE: KDST), a clinical stage . Seite 1
Investegate announcements from Kadimastem, Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells
DGAP-News: Kadimastem Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of "Immune Evasive" Cells 08.06.2022 / 13:00 The issuer